Hangzhou Diagens Biotechnology Co Ltd

02526

Company Profile

  • Business description

    Hangzhou Diagens Biotechnology Co Ltd and its subsidiaries are involved in the development and commercialisation of medical imaging artificial intelligence technologies and medical imaging equipment. It has self-developed a diversified portfolio, including six medical imaging software products, three commercialized medical devices, four key reagents and consumables and two technology licensing offerings. Its Core Product, AI AutoVision, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping. The majority of the company's revenue is derived from Technology Licensing, mainly in the Chinese mainland.

  • Contact

    No. 609 Hongfeng Road
    Room 101, Building 1
    Donghu Sub-district
    Linping District, Zhejiang
    Hangzhou
    CHN

    T: +86 4000680888

    https://www.diagens.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    182

Stocks News & Analysis

stocks

OpenAI is going public as the worst value among its peers

Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks

Wide moat healthcare leader remains undervalued

ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks

This US AI winner has been unstoppable. Is it time to sell?

Astonishing results have driven this AI stock into significantly overvalued territory.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,855.9079.60-0.89%
CAC 408,226.418.170.10%
DAX 4024,689.6669.39-0.28%
Dow JONES (US)51,066.63199.850.39%
FTSE 10010,375.237.180.07%
HKSE24,657.06304.89-1.22%
NASDAQ26,028.51319.081.24%
Nikkei 22564,024.602,563.52-3.85%
NZX 50 Index13,038.24123.73-0.94%
S&P 5007,445.2061.460.83%
S&P/ASX 2008,625.1080.00-0.92%
SSE Composite Index3,959.3468.40-1.70%

Market Movers